Guoxin Du
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Guoxin Du has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Donglei Zhang
Department of Surgery, McGill University Health Center, The Royal Victoria Hospital, Montreal, Quebec, Canada
1 shared publication Feifei Hao
Shenyang Industrial Technology Institute of Ophthalmology, Shenyang, PR China
1 shared publicationHualiang Jiang
Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, PR China
1 shared publication- Mingyue Zheng
Shanghai Institute of Materia Medica, Chinese Academy of Sciences
1 shared publication Minnan Wang
Shenyang He Vision Industrial Group Co.,Ltd, Shenyang, PR China
1 shared publicationQi Gong
Shenyang Industrial Technology Institute of Ophthalmology, Shenyang, PR China
1 shared publication
Latest Publications
- 17 February 2022
- Published by Springer Nature in Medicinal Chemistry Research
- Vol. 31 (4) , 555-579
Design, synthesis, and LFA-1/ICAM-1 antagonist activity evaluation of Lifitegrast analogues
The interaction between Lymphocyte function-associated antigen 1 (LFA-1) and intercellular-adhesion molecule-1 (ICAM-1) plays important roles in the cell-mediated immune response and inflammation associated with dry eye disease. LFA-1/ICAM-1 antagonists can be used for the treatment of dry eye disease, such as Lifitegrast which has been approved by the FDA in 2016 as a new drug for the treatment of dry eye disease. In this study, we designed and synthesized some new structure compounds that are analogues to Lifitegrast, and their biological activities were evaluated by in vitro cell-based assay and also by in vivo mouse dry eye model. Our results demonstrated that one of these analogues of Lifitegrast (compound 1b) showed good LFA-1/ICAM-1 antagonist activity in in vitro assay; meanwhile, it also significantly reduced ocular surface epithelial cells damage, increased goblet cell density in dry eye mouse and highly improved the symptoms of dry eye mouse. Graphical abstract
- 17 February 2022
- Published by Springer Nature in Medicinal Chemistry Research
- Vol. 31 (4) , 555-579
Design, synthesis, and LFA-1/ICAM-1 antagonist activity evaluation of Lifitegrast analogues
The interaction between Lymphocyte function-associated antigen 1 (LFA-1) and intercellular-adhesion molecule-1 (ICAM-1) plays important roles in the cell-mediated immune response and inflammation associated with dry eye disease. LFA-1/ICAM-1 antagonists can be used for the treatment of dry eye disease, such as Lifitegrast which has been approved by the FDA in 2016 as a new drug for the treatment of dry eye disease. In this study, we designed and synthesized some new structure compounds that are analogues to Lifitegrast, and their biological activities were evaluated by in vitro cell-based assay and also by in vivo mouse dry eye model. Our results demonstrated that one of these analogues of Lifitegrast (compound 1b) showed good LFA-1/ICAM-1 antagonist activity in in vitro assay; meanwhile, it also significantly reduced ocular surface epithelial cells damage, increased goblet cell density in dry eye mouse and highly improved the symptoms of dry eye mouse. Graphical abstract